Results 21 to 30 of about 39,460 (147)

Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation

Hepatology, 2020
Altered bile acid (BA) homeostasis is an intrinsic facet of cholestatic liver diseases, but clinical usefulness of plasma BA assessment in primary sclerosing cholangitis (PSC) remains understudied.
O. Mousa, B. Juran, Bryan M McCauley, M. Vesterhus, T. Folseraas, Coleman T. Turgeon, A. Ali, E. Schlicht, E. Atkinson, Chang Hu, D. Harnois, E. Carey, A. Gossard, D. Oglesbee, J. Eaton, N. LaRusso, G. Gores, T. Karlsen, K. Lazaridis   +18 more
semanticscholar   +1 more source

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa? A randomized, placebo-controlled study [PDF]

, 2003
Background: In animal models ursodeoxycholic acid (UDCA) showed a chemoprotective effect against colon cancer. To explain this, a reduced proliferation of the colorectal mucosal proliferation was suggested.
Diebold, J., Göke, B., Hay, U., Marsteller, I., Ochsenkühn, Thomas, Paumgartner, Gustav, Sackmann, M.   +6 more
core   +1 more source

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

Hepatology, 2020
Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC.
B. Goeppert, T. Folseraas, S. Roessler, Matthias Kloor, Anna‐Lena Volckmar, Volker Endris, Ivo Buchhalter, Albrecht Stenzinger, Krzysztof Grzyb, Marit M. Grimsrud, Barbara Górnicka, E. Seth, Gary M. Reynolds, André Franke, Daniel N. Gotthardt, A. Mehrabi, Angela C. Cheung, Joanne Verheij, Johanna Arola, Heikki Mäkisalo, T. Eide, S. Weidemann, J. Cheville, Giuseppe Mazza, G. Hirschfield, C. Ponsioen, A. Bergquist, P. Milkiewicz, K. Lazaridis, Christoph Schramm, Michael P. Manns, Martti A Färkkilä, Arndt Vogel, K. Boberg, Peter Schirmacher, T. Karlsen   +35 more
semanticscholar   +1 more source

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

Journal of gastroenterology, 2020
Primary sclerosing cholangitis (PSC) is a progressive liver disease, histologically characterized by inflammation and fibrosis of the bile ducts, and clinically leading to multi-focal biliary strictures and with time cirrhosis and liver failure. Patients
M. Vesterhus, T. Karlsen
semanticscholar   +1 more source

Serum micrornas as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma [PDF]

, 2016
The diagnosis of primary sclerosing cholangitis (PSC) is difficult due to the lack of sensitive and specific biomarkers, as is the early diagnosis of cholangiocarcinoma (CC), a complication of PSC.
Alpini, Gianfranco, Alvaro, Domenico, Bernuzzi, Francesca, Bowlus, Christopher L, Carbone, Marco, Eric Gershwin, M, He, Xiao Song, Invernizzi, Pietro, Lleo, Ana, Locati, Massimo, Marabita, Francesco, Marzioni, Marco, Mirolo, Massimiliano, Muri Boberg, Kirsten, Piscaglia, Fabio, Rimassa, Lorenza, Torzilli, Guido, Yang, Guo Xiang   +17 more
core   +2 more sources

Controversies in the management of primary sclerosing cholangitis [PDF]

, 2016
Primary sclerosing cholangitis (PSC) remains a rare but significant disease, which affects mainly young males in association with inflammatory bowel disease.
Devlin, J, Harrison, PM, Joshi, D, Nayagam, JS, Pereira, SP   +4 more
core   +1 more source

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Hepatology, 2019
Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double‐blind, placebo‐controlled study, we tested the safety and efficacy of cilofexor (formerly GS‐9674), a nonsteroidal farnesoid X receptor agonist in patients ...
M. Trauner, A. Gulamhusein, B. Hameed, S. Caldwell, M. Shiffman, C. Landis, B. Eksteen, K. Agarwal, A. Muir, S. Rushbrook, Xiaomin Lu, Jun Xu, J. Chuang, A. Billin, Georgia Li, C. Chung, G. Subramanian, Robert P. Myers, C. Bowlus, K. Kowdley   +19 more
semanticscholar   +1 more source

Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework

American Journal of Gastroenterology, 2020
Primary sclerosing cholangitis (PSC) is a rare, immune-mediated, chronic cholestatic liver disease associated with a unique phenotype of inflammatory bowel disease that frequently manifests as pancolitis with right-sided predominance.
A. Shah, G. Macdonald, M. Morrison, G. Holtmann   +3 more
semanticscholar   +1 more source

MAIT cells come to the rescue in cancer immunotherapy? [PDF]

, 2020
Recent progress in immunobiology has led to the observation that, among cells classically categorized as the typical representatives of the adaptive immune system, i.e., T cells, some possess the phenotype of innate cells.
Elewaut, Dirk, Venken, Koen, Łukasik, Zuzanna   +2 more
core   +2 more sources

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

Gut, 2019
These guidelines on the management of primary sclerosing cholangitis (PSC) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included medical representatives from hepatology and gastroenterology ...
M. Chapman, D. Thorburn, G. Hirschfield, G. Webster, S. Rushbrook, G. Alexander, J. Collier, J. Dyson, David E. J. Jones, I. Patanwala, Collette Thain, Martine Walmsley, S. Pereira   +12 more
semanticscholar   +1 more source